The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.
Howard I. Scher
Consultant or Advisory Role - Medivation (U)
Research Funding - Medivation
Karim Fizazi
No relevant relationships to disclose
Fred Saad
Consultant or Advisory Role - Medivation
Honoraria - Medivation
Research Funding - Medivation
Mary-Ellen Taplin
Consultant or Advisory Role - Medivation; Medivation
Research Funding - Medivation; Medivation
Cora N. Sternberg
No relevant relationships to disclose
Kurt Miller
Consultant or Advisory Role - Astellas Pharma; Medivation
Honoraria - Astellas Pharma
Ronald De Wit
No relevant relationships to disclose
Peter Mulders
Disclosure not yet available
Mohammad Hirmand
Employment or Leadership Position - Medivation
Bryan Selby
Employment or Leadership Position - Medivation
Johann Sebastian De Bono
Employment or Leadership Position - Institute of Cancer Research; Institute of Cancer Research
Consultant or Advisory Role - Astellas Pharma; Astellas Pharma; Johnson & Johnson; Johnson & Johnson; Medivation; Medivation
Honoraria - Astellas Pharma; Astellas Pharma; Johnson & Johnson; Johnson & Johnson; Medivation; Medivation